BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 34556152)

  • 1. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway.
    Ji F; Zhang F; Zhang M; Long K; Xia M; Lu F; Li E; Chen J; Li J; Chen Z; Jing L; Jia S; Yang R; Hu Z; Guo Z
    J Hematol Oncol; 2021 Sep; 14(1):152. PubMed ID: 34556152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
    Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
    Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
    [No Abstract]   [Full Text] [Related]  

  • 3. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.
    Xiong Q; Wang H; Shen Q; Wang Y; Yuan X; Lin G; Jiang P
    J Transl Med; 2024 Apr; 22(1):368. PubMed ID: 38637886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma.
    Panowski SH; Srinivasan S; Tan N; Tacheva-Grigorova SK; Smith B; Mak YSL; Ning H; Villanueva J; Wijewarnasuriya D; Lang S; Melton Z; Ghosh A; Dusseaux M; Galetto R; Heyen JR; Sai T; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Cancer Res; 2022 Jul; 82(14):2610-2624. PubMed ID: 35294525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.
    Sauer T; Parikh K; Sharma S; Omer B; Sedloev D; Chen Q; Angenendt L; Schliemann C; Schmitt M; Müller-Tidow C; Gottschalk S; Rooney CM
    Blood; 2021 Jul; 138(4):318-330. PubMed ID: 34323938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD70, a novel target of CAR T-cell therapy for gliomas.
    Jin L; Ge H; Long Y; Yang C; Chang YE; Mu L; Sayour EJ; De Leon G; Wang QJ; Yang JC; Kubilis PS; Bao H; Xia S; Lu D; Kong Y; Hu L; Shang Y; Jiang C; Nie J; Li S; Gu Y; Sun J; Mitchell DA; Lin Z; Huang J
    Neuro Oncol; 2018 Jan; 20(1):55-65. PubMed ID: 28651374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
    Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
    J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.
    Wang QJ; Yu Z; Hanada KI; Patel K; Kleiner D; Restifo NP; Yang JC
    Clin Cancer Res; 2017 May; 23(9):2267-2276. PubMed ID: 27803044
    [No Abstract]   [Full Text] [Related]  

  • 9. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia.
    Wu G; Guo S; Luo Q; Wang X; Deng W; Ouyang G; Pu JJ; Lei W; Qian W
    Front Immunol; 2023; 14():1093750. PubMed ID: 36845088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
    Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts.
    Van den Eynde A; Gehrcken L; Verhezen T; Lau HW; Hermans C; Lambrechts H; Flieswasser T; Quatannens D; Roex G; Zwaenepoel K; Marcq E; Joye P; Cardenas De La Hoz E; Deben C; Gasparini A; Montay-Gruel P; Le Compte M; Lion E; Lardon F; Van Laere S; Siozopoulou V; Campillo-Davo D; De Waele J; Pauwels P; Jacobs J; Smits E; Van Audenaerde JRM
    J Hematol Oncol; 2024 Feb; 17(1):8. PubMed ID: 38331849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STING agonist promotes CAR T cell trafficking and persistence in breast cancer.
    Xu N; Palmer DC; Robeson AC; Shou P; Bommiasamy H; Laurie SJ; Willis C; Dotti G; Vincent BG; Restifo NP; Serody JS
    J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33382402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.
    Hu X; Zhao M; Bai M; Xue Z; Wang F; Zhu Z; Yu J; Yue J
    Cancer Lett; 2024 Apr; 586():216676. PubMed ID: 38278469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.
    Wang QJ; Hanada K; Robbins PF; Li YF; Yang JC
    Cancer Res; 2012 Dec; 72(23):6119-29. PubMed ID: 23071066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma.
    Benhamouda N; Sam I; Epaillard N; Gey A; Phan L; Pham HP; Gruel N; Saldmann A; Pineau J; Hasan M; Quiniou V; Nevoret C; Verkarre V; Libri V; Mella S; Granier C; Broudin C; Ravel P; De Guillebon E; Mauge L; Helley D; Jabla B; Chaput N; Albiges L; Katsahian S; Adam J; Mejean A; Adotevi O; Vano YA; Oudard S; Tartour E
    Clin Cancer Res; 2022 Nov; 28(22):4983-4994. PubMed ID: 36067339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies.
    Shaffer DR; Savoldo B; Yi Z; Chow KK; Kakarla S; Spencer DM; Dotti G; Wu MF; Liu H; Kenney S; Gottschalk S
    Blood; 2011 Apr; 117(16):4304-14. PubMed ID: 21304103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor efficacy of human anti-c-met CAR-T cells against papillary renal cell carcinoma in an orthotopic model.
    Mori JI; Adachi K; Sakoda Y; Sasaki T; Goto S; Matsumoto H; Nagashima Y; Matsuyama H; Tamada K
    Cancer Sci; 2021 Apr; 112(4):1417-1428. PubMed ID: 33539630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma.
    Zhu G; Zhang J; Zhang Q; Jin G; Su X; Liu S; Liu F
    Cancer Immunol Immunother; 2022 Oct; 71(10):2433-2448. PubMed ID: 35249119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.
    Adam PJ; Terrett JA; Steers G; Stockwin L; Loader JA; Fletcher GC; Lu LS; Leach BI; Mason S; Stamps AC; Boyd RS; Pezzella F; Gatter KC; Harris AL
    Br J Cancer; 2006 Aug; 95(3):298-306. PubMed ID: 16892042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer.
    Shen D; Luo J; Chen L; Ma W; Mao X; Zhang Y; Zheng J; Wang Y; Wan J; Wang S; Ouyang J; Yi H; Liu D; Huang W; Zhang W; Liu Z; McLeod HL; He Y
    Cancer Lett; 2022 Dec; 550():215919. PubMed ID: 36116741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.